# Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer

> **NCT06459921** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Neoadjuvant Chemotherapy
- Sintilimab
- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** SOX+Sintilimab
- **DRUG:** FLOT+Sintilimab

## Key facts

- **NCT ID:** NCT06459921
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06459921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06459921, "Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06459921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*